Continuous hyperthermic peritoneal perfusion (CHPP) for malignant ascites and irresectable intra-abdominal cancer.
Ben-Ari
G
G
Dept. of Surgical Oncology, Chaim Sheba Medical Center, Israel.
Scott
D
D
Zippel
D
D
Sareli
M
M
Koller
M
M
Papa
M
M
D000008:Abdominal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000401:mortality / Q000628:therapy*; D002455:Cell Division; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral / Q000379:methods; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010477:Perfusion; D015996:Survival Rate
D016685:Mitomycin; D002945:Cisplatin; D008558:Melphalan; D005472:Fluorouracil